Pay in 4 interest-free payments of $7.20 Learn more
Ships within 48 hours · Estimated delivery Oct 28 - Nov 2
Recently viewed No recently viewed products
(Exenatide is FDA approved as monotherapy for the management of T2DM.) Explicitly stated in the guideline for patients requiring dual or triple therapy, the AACE/ACE preferentially recommends the addition of a GLP-1 receptor agonist or a DPP-4 inhibitor (sitagliptin, saxagliptin), citing their efficacy and safety profiles as preferred agents over TZDs or sulfonylureas (SUs)
Explore Detailed Profiles of Industry Competitors The GLP-1 Agonist Market is about to change a lot in the next ten years
LuoYLiuLZhaoJJiaoYZhangMXuGet al
L., Neyrinck, A
US$ 21.09
US$ 23.02
US$ 28.29
US$ 28.85
